You are here: Home > Institute of Excellence (CPD) > CPD Events > Advancing Geographic Atrophy Diagnosis: Imaging, Biomarkers & AI in Clinical Practice Video

Advancing Geographic Atrophy Diagnosis: Imaging, Biomarkers & AI in Clinical Practice VIDEO

Available from: 7/04/2026 (AEST)

Where to publish: www.mieducation.com

Provider: Mivision

Contact: Nikki Byrne, [E] nikki@mivision.com.au, [P] 02 8336 8616

Activity Outline

Stay ahead in AMD and GA care—master multimodal imaging, identify high-risk biomarkers, and discover how AI is shaping the future of diagnosis and patient management.

This virtual webinar provides an in-depth educational update on the evolving landscape of diagnosing Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD). The session will focus on recognizing high-risk biomarkers, understanding differential diagnoses, and leveraging advanced diagnostic equipment such as Optical Coherence Tomography (OCT), Fundus Autofluorescence (FAF), and Retinal Photography to improve patient care.

Participants will gain a comprehensive understanding of multimodal imaging techniques used to assess and monitor AMD and GA, including the advantages and limitations of each modality. The program will build confidence in interpreting diagnostic test results and identifying structural biomarkers that may predict disease progression. Additionally, the webinar will address practical strategies for classifying AMD patients, with emphasis on referral criteria for ophthalmology, and explore key considerations in differential diagnoses for GA.

The session will also highlight the role of artificial intelligence (AI) and machine learning in enhancing diagnostic assistance and image analysis. Attendees will learn about practical applications of AI-driven tools, how these technologies can be evaluated for clinical use, and strategies for integrating them into existing clinical reasoning frameworks to support decision-making and optimize patient management.

The session will open with Professor Anthony Kwan, followed by Optometrists Inez Hsing and Professor James Armitage, who will share their real-world insights through case-based discussions, offering practical strategies and examples to help stay at the forefront of GA diagnosis and management

This educational update is designed for eye care professionals seeking to deepen their knowledge of imaging modalities, improve diagnostic accuracy, and understand the future impact of AI in Geography Atrophy.


Learning Objectives

  • To have a comprehensive understanding of different multimodal imaging techniques in assessing and monitoring patients with age-related macular degeneration (AMD) and geographic atrophy (GA), and the advantages and disadvantages of each modality
  • To gain confidence in interpreting diagnostic testing results, and identify various structural biomarkers that may help to be predict progression risk
  • To better understand how to classify AMD patients, with particular emphasis on when referral to ophthalmology may be indicated
  • To better understand differential diagnoses in GA
  • To understand how AI and machine learning can enhance diagnostic assistance and image analysis in AMD and GA, including practical applications and evaluation of diagnostic support tools.
  • To learn strategies for integrating AI-driven tools into existing clinical reasoning frameworks to support decision-making and improve patient management.

Max CPD hours awarded: 2.25

Session Information

Name
Advancing Geographic Atrophy Diagnosis: Imaging, Biomarkers & AI in Clinical Practice VIDEO
Clinical?
Yes
Interactive?
No
Therapeutic?
Yes
Duration of CPD Session/Module
2
Duration of CPD Session/Module inclusive of Assessment Component
2.25

Acknowledgement of Country

In the spirit of reconciliation Optometry Australia acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respects to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.